275 related articles for article (PubMed ID: 31418414)
21. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications?
Chung HH; Razavi MK; Sze DY; Frisoli JK; Kee ST; Dake MD; Hellinger JC; Kang BC
J Gastroenterol Hepatol; 2008 Jan; 23(1):95-101. PubMed ID: 18171347
[TBL] [Abstract][Full Text] [Related]
22. The combination of Child-Pugh score and quantitative CT-based spleen volume could predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation.
Liu J; Zhou C; Wang Y; Yang C; Shi Q; Huang S; Chen Y; Li T; Xiong B
Abdom Radiol (NY); 2021 Jul; 46(7):3464-3470. PubMed ID: 33660042
[TBL] [Abstract][Full Text] [Related]
23. [Study of portal venous pressure gradient to predict high-hepatic encephalopathy-risk population post TIPS].
Zhang H; Pan JJ; Jiang XF; Lin JJ; Lu LJ; Chu JG
Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):72-74. PubMed ID: 33548970
[TBL] [Abstract][Full Text] [Related]
24. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy.
Pereira K; Carrion AF; Martin P; Vaheesan K; Salsamendi J; Doshi M; Yrizarry JM
Liver Int; 2015 Dec; 35(12):2487-94. PubMed ID: 26332169
[TBL] [Abstract][Full Text] [Related]
25. Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study.
Yang Y; Fu S; Cao B; Hao K; Li Y; Huang J; Shi W; Duan C; Bai X; Tang K; Yang S; He X; Lu L
Hepatol Int; 2021 Jun; 15(3):730-740. PubMed ID: 33977364
[TBL] [Abstract][Full Text] [Related]
26. A nomogram to predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in Cirrhotic Patients.
Yin X; Zhang F; Guo H; Peng C; Zhang W; Xiao J; Wang Y; Zou X; Zhang M; Zhuge Y
Sci Rep; 2020 Jun; 10(1):9381. PubMed ID: 32523059
[TBL] [Abstract][Full Text] [Related]
27. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
[TBL] [Abstract][Full Text] [Related]
28. Refractory Hepatic Encephalopathy After Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors and Outcomes with Revision.
Rowley MW; Choi M; Chen S; Hirsch K; Seetharam AB
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1765-1772. PubMed ID: 29872892
[TBL] [Abstract][Full Text] [Related]
29. Psoas Muscle Density Predicts Occurrences of Hepatic Encephalopathy in Patients Receiving Transjugular Intrahepatic Portosystemic Shunts within 1 year.
Cai W; Lin H; Qi R; Lin X; Zhao Y; Chen W; Huang Z
Cardiovasc Intervent Radiol; 2022 Jan; 45(1):93-101. PubMed ID: 34523022
[TBL] [Abstract][Full Text] [Related]
30. Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt.
Yin L; Chu SL; Lv WF; Zhou CZ; Liu KC; Zhu YJ; Zhang WY; Wang CX; Zhang YH; Lu D; Cheng DL
World J Gastroenterol; 2023 May; 29(18):2875-2887. PubMed ID: 37274064
[TBL] [Abstract][Full Text] [Related]
31. Transjugular intrahepatic portosystemic shunt treatment of variceal bleeding in an unselected patient population.
Rosenqvist K; Sheikhi R; Nyman R; Rorsman F; Sangfelt P; Ebeling Barbier C
Scand J Gastroenterol; 2018 Jan; 53(1):70-75. PubMed ID: 28990812
[TBL] [Abstract][Full Text] [Related]
32. Transjugular intrahepatic portosystemic shunt does not alter cerebral blood flow.
Iversen P; Keiding S; Mouridsen K; Ott P; Vilstrup H
Clin Gastroenterol Hepatol; 2011 Nov; 9(11):1001-3. PubMed ID: 21806953
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of albumin-bilirubin score to predict hepatic encephalopathy in patients underwent transjugular intrahepatic portosystemic shunt.
Lin X; Gao F; Wu X; Cai W; Chen X; Huang Z
Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):862-871. PubMed ID: 32541240
[TBL] [Abstract][Full Text] [Related]
34. Prediction of Mortality and Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Placement: Baseline and Longitudinal Body Composition Measurement.
Tuifua TS; Kapoor B; Partovi S; Shah SN; Bullen JA; Enders J; Laique S; Levitin A; Gadani S
J Vasc Interv Radiol; 2024 May; 35(5):648-657.e1. PubMed ID: 38244917
[TBL] [Abstract][Full Text] [Related]
35. Low adipose tissue index as an indicator of hepatic encephalopathy in cirrhotic patients following transjugular intrahepatic portosystemic shunt.
Wang C; Teng Y; Gao J; Zhang Z; Li Y
Abdom Radiol (NY); 2023 Apr; 48(4):1454-1467. PubMed ID: 36735033
[TBL] [Abstract][Full Text] [Related]
36. [Follow-up study of 116 cases of transjugular intrahepatic portosystemic shunt in the treatment of cirrhotic portal hypertension].
Liu MH; Zhou F; Wang XB; Chen LP; Li GZ; Zhao Q
Zhonghua Gan Zang Bing Za Zhi; 2018 Aug; 26(8):596-600. PubMed ID: 30317791
[No Abstract] [Full Text] [Related]
37. Transjugular intrahepatic portosystemic shunt in refractory hydrothorax - a contribution to an unexplored indication.
Campos S; Gomes D; Sofia C
Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):661-6. PubMed ID: 27002676
[TBL] [Abstract][Full Text] [Related]
38. Transjugular intrahepatic portosystemic shunt: A promising therapy for recompensation in cirrhotic patients.
Jin YN; Zhang W
World J Gastroenterol; 2024 Apr; 30(16):2285-2286. PubMed ID: 38690019
[TBL] [Abstract][Full Text] [Related]
39. Early-Recurrent Overt Hepatic Encephalopathy Is Associated with Reduced Survival in Cirrhotic Patients after Transjugular Intrahepatic Portosystemic Shunt Creation.
Zuo L; Lv Y; Wang Q; Yin Z; Wang Z; He C; Guo W; Niu J; Bai W; Li K; Yu T; Yuan X; Chen H; Liu H; Xia D; Wang E; Luo B; Li X; Yuan J; Han N; Nie Y; Fan D; Han G
J Vasc Interv Radiol; 2019 Feb; 30(2):148-153.e2. PubMed ID: 30638778
[TBL] [Abstract][Full Text] [Related]
40. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
